Find a Tender
active
Official procurement procedure
Medicines Licensing Assessor Services
Medical analysis services
Research and development services and related consultancy services
Location not published
Published value
£10,000,000
Submission deadline 6 Aug 2026, 12:00 BST
Lots published3
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: MHRA: "Medicines Licensing Assessor Services". Published status: active. Published value: £10,000,000. 3 published lots. Recorded submission deadline: 6 Aug 2026, 12:00 BST. See the official notice for participation instructions.
| Contracting Authority | MHRA | Scope & Categories | Not published | Submission Window | Closed 6 Aug 2026, 12:00 BST |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | £10,000,000 |
Bidder Intelligence · Authority Profile: MHRA
Market Analytics
Derived from OCDS awards & bid statistics
Published history for MHRA. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
5.7Bids / Report
Supplier ConcentrationHigh Concentration
Parker Air Conditioning LtdTop vendor: 71.4% of attributable valuePayment Terms
Check noticePublished terms
Coverage: 34 active published awards; 3 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Historical Awarded Suppliers With This Authority:
| Supplier Name | Historic Awards | Attributable GBP Value |
|---|---|---|
| Parker Air Conditioning Ltd | 1 win | £300,000 |
| Spirax Sarco Limited | 1 win | £90,000 |
| Honeyman Water Limited | 1 win | £30,187 |
Procedure terms
Contracting AuthorityMHRA | Procedure methodNot published | Procurement categoryNot published |
Statusactive | Framework / DPSFramework | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published3 Jul 2026, 07:48 BST | Last source update3 Jul 2026, 07:48 BST | Recurring procurementNot published |
ClassificationMedical analysis services, Research and development services and related consultancy services | ||
Delivery areaLocation not published | ||
OCIDocds-h6vhtk-060643 | ||
What is being bought
The Medicines and Healthcare products Regulatory Agency is the regulator of medicines, medical devices and blood components for transfusion in the UK. MHRA carries out a wide range of activities to fulfil its role as a patient safety regulator. This includes carrying out assessments of the safety, quality and efficacy of medicines, assessing the safety of proposed clinical trials of medicines and medical devices, inspecting the premises of those manufacturing, supplying or distributing medicines and monitoring the ongoing safety of all medical products, taking swift action where necessary to prevent harm to patients. The MHRA also engages with companies within the regulated sector to provide specific, scientific advice on the development of products. The aim of such advice is to ensure the developer understands the requirements of the regulator, ensuring that the developer can provide the required information to support a properly informed assessment.
With a wide range of critical deliverables, MHRA is seeking opportunities to add to its traditional in-house expertise through the establishment of additional sources of both capacity and capability. These will enable MHRA to deliver innovative, new and improved services at increased pace, safeguarding public health and supporting the growth of life sciences in the UK.
MHRA is seeking suppliers with the capacity and capability to deliver assessments of complex clinical and non-clinical regulatory data and provide carefully evidenced judgements within an MHRA assessment and quality assurance framework. Such assessments may relate to marketing authorisation applications, clinical trial applications and a variety of other compliance activities. Deployment of supplier resources will be on a flexible basis to enable MHRA greater discretion in flexing established capacity as needed to support increased growth in UK life sciences through new and improved advice and support services.
To achieve this ambition, MHRA wishes to establish a framework of specialist providers, which cover 3 Lots. Up to four suppliers, who meet the minimum criteria, may be awarded a place on each Lot.
Lot 1: Pharmaceutical Assessment: Assessment of pharmaceutical/quality data (in compliance with Module 3 and Module 2 (sections relevant to Quality) of the Common Technical Document).
Lot 2: Medical Assessment: Assessment of clinical, statistical and clinical pharmacology data (in compliance with Module 5 and Module 2 (sections relevant to Clinical) of the Common Technical Document).
Lot 3: Non-Clinical Assessment: Assessment of non-clinical data (in compliance with Module 4 of the Common Technical Document).
What changed
From the official release history
- Official notice release published
3 Jul 2026, 07:48 BST - Published value updated to £10,000,000
1 Jul 2026, 18:18 BST - Status changed to active
1 Jul 2026, 18:18 BST - Official notice release published
1 Jul 2026, 18:18 BST - Submission deadline changed to 6 Aug 2026, 12:00 BST
1 Jul 2026, 18:18 BST - Status changed to planning
15 Jan 2026, 09:42 GMT - Official notice release published
15 Jan 2026, 09:42 GMT - Buyer information updated
15 Jan 2026, 09:42 GMT - Published tender amendment
Not publishedAmendment to internal reference.
Lots and requirements (3)
Published by the contracting authority
- Lot 1 · #1Pharmaceutical AssessmentactivePublished value£5,000,000Assessment of pharmaceutical/quality data (in compliance with Module 3 and Module 2 (sections relevant to Quality) of the Common Technical Document).Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 2 · #2Medical AssessmentactivePublished value£4,000,000Assessment of clinical, statistical and clinical pharmacology data (in compliance with Module 5 and Module 2 (sections relevant to Clinical) of the Common Technical Document).Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 3 · #3Non-Clinical AssessmentactivePublished value£1,000,000Assessment of non-clinical data (in compliance with Module 4 of the Common Technical Document).Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
3 Jul 2026, 07:48 BST - Submission deadline
6 Aug 2026, 12:00 BST
Commercial outcome and competition
AwardsNo award published |
ContractsNo contract published |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
MHRA
Contracting authority GB-PPON-PJLJ-9824-VXPGDocuments (2)
Official links; attachments are not copied
- 3 Jul 2026, 07:48 BST
Related procedures (0)
No related procedures published